- Home
- HOTH vs IBIO Comparison
HOTH vs IBIO Comparison
Compare HOTH & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOTH
- IBIO
- Stock Information
- Founded
- HOTH 2017
- IBIO 2008
- Country
- HOTH United States
- IBIO United States
- Employees
- HOTH N/A
- IBIO N/A
- Industry
- HOTH Biotechnology: Pharmaceutical Preparations
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- HOTH Health Care
- IBIO Health Care
- Exchange
- HOTH Nasdaq
- IBIO Nasdaq
- Market Cap
- HOTH 15.6M
- IBIO 16.4M
- IPO Year
- HOTH 2019
- IBIO N/A
- Fundamental
- Price
- HOTH $1.51
- IBIO $0.85
- Analyst Decision
- HOTH Strong Buy
- IBIO Strong Buy
- Analyst Count
- HOTH 3
- IBIO 2
- Target Price
- HOTH $4.00
- IBIO $5.50
- AVG Volume (30 Days)
- HOTH 1.3M
- IBIO 394.8K
- Earning Date
- HOTH 11-11-2025
- IBIO 11-11-2025
- Dividend Yield
- HOTH N/A
- IBIO N/A
- EPS Growth
- HOTH N/A
- IBIO N/A
- EPS
- HOTH N/A
- IBIO N/A
- Revenue
- HOTH N/A
- IBIO $400,000.00
- Revenue This Year
- HOTH N/A
- IBIO N/A
- Revenue Next Year
- HOTH N/A
- IBIO N/A
- P/E Ratio
- HOTH N/A
- IBIO N/A
- Revenue Growth
- HOTH N/A
- IBIO 77.78
- 52 Week Low
- HOTH $0.65
- IBIO $0.56
- 52 Week High
- HOTH $3.80
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- HOTH 44.02
- IBIO 55.24
- Support Level
- HOTH $1.49
- IBIO $0.78
- Resistance Level
- HOTH $1.62
- IBIO $0.86
- Average True Range (ATR)
- HOTH 0.14
- IBIO 0.04
- MACD
- HOTH -0.05
- IBIO -0.00
- Stochastic Oscillator
- HOTH 6.11
- IBIO 63.51
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.